Evonik Industries (XTRA:EVK) Stock Faces Valuation Scrutiny After EBITDA Rebound

Evonik Industries heads into this earnings season with the stock at €17.87 after a solid run over the past month, yet the real story sits inside the latest report. Q2 2026 produced adjusted earnings before interest, taxes, depreciation and amortization of €630m, which management describes as the strongest quarter in four years and enough to justify an upgraded full year outlook. For a company trading on a P/E of 68.8x with a dividend yield of 5.6%, this quarter is less about a single share price move and more about whether the profit rebound can support that valuation over several years.

Love Evonik Industries' strong Q2 rebound and income appeal, but uneasy about paying a P/E of 68.8x for that story alone? Check out the 245 high quality undervalued stocks to compare this set up with other stocks that combine quality, income potential and more modest valuations.

Q2 2026 Earnings Summary

• Revenue Q2 2026 vs. Q2 2025: €3,893m vs. €3,499m (up 11.3%)
• Net Income Q2 2026 vs. Q2 2025: €84m vs. €120m (down 30.0%)
• Basic EPS Q2 2026 vs. Q2 2025: €0.18 vs. €0.26 (down 30.8%)
• Adjusted EBITDA Q2 2026 vs. Q2 2025: €630m vs. approximately €508m (up 24%)

Tired of scanning pages of earnings tables and dense commentary to figure out what really matters for Evonik Industries? Get the full visual picture of the stock, including how the current valuation compares with its recent earnings rebound, in our company report for Evonik Industries.

Evonik bull case: specialty pivot finally biting

Bulls argue Evonik Industries is turning into a higher quality specialty chemicals group, with methionine, silica and healthcare style businesses steadily taking over the earnings mix. Q2 gives some backing to that view. Adjusted EBITDA of €630m, the best in four years, is driven mainly by Advanced Technologies, where methionine, crosslinkers, polymers and PA12 all contribute. Higher volumes and higher prices each add roughly 7 percentage points, which suggests pricing power and demand in the more technical portfolio rather than just cost cutting. Cost programs, including earlier FTE reductions and footprint work in silica and U.S. methionine integration, are feeding through to margins and cash conversion. Management is comfortable enough to raise the full year EBITDA midpoint, which is consistent with a portfolio that is starting to lean more on specialty earnings instead of older commodity exposure.

Evonik bear case: cyclicality and restructuring still bite

The bear story claims Evonik is still too tied to cyclical and weaker commodity assets, with restructuring risk and volatile earnings under the surface. Parts of Q2 support that caution. Net income falls to €84m from €120m, and basic EPS drops from €0.26 to €0.18 even as adjusted EBITDA rises. That gap reflects heavier restructuring and impairment, including the Oxeno write down and Witten closure provision, which show that underperforming C4 and related activities are still a drag and require cash and management focus. Custom Solutions is only expected to be broadly stable for 2026 rather than slightly higher as previously guided, with additives normalizing and refinery catalysts soft. Management also flags weak visibility in several pockets and a likely softer Q4. The upgraded EBITDA outlook does not fully remove the concern that a chunk of earnings is exposed to cyclical swings and ongoing cleanup costs.

After restructuring costs, a high P/E and tight dividend cover at Evonik Industries, it is worth asking whether these are isolated issues or part of a broader pattern. Review the independent risk analysis for Evonik Industries which shows 4 important warning signs

Stay Ahead With Simply Wall St

If Evonik Industries' mix of a high P/E, strong Q2 adjusted EBITDA and ongoing restructuring has caught your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a better entry point. Once you decide to buy or add to a position, use the Portfolio Command Center to cut through market noise and focus on the most important changes to your holdings. For longer term investors, the Community helps you see how other investors are thinking about risks and opportunities across different stocks. By spotting potential catalysts and warning signs early, you give yourself a better chance of staying ahead of the market rather than reacting to it late.

Seeking Alternatives Beyond Evonik Industries

Fresh ideas can move fast. Some stocks are breaking out while interest is still low and information is freshest. Do not get caught watching from the sidelines, act now.

• Spot companies with strong cash generation before attention piles in by scanning our curated list of solid balance sheet and fundamentals stocks (417 results), which may hold up better when enthusiasm fades elsewhere.
• Catch potential income workhorses while yields are still appealing with the hand picked 440 dividend fortresses, which focuses on consistency and balance sheet strength.
• Ride early momentum in automation and efficiency trends through a focused set of 36 robotics and automation stocks, which could benefit as spending on productivity keeps building.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com